MedDataX Logo

Halt Aging in Survivors of Blood Cancers: the HALTAging-1 Study

NCT ID: NCT07292272

Last Updated: 2025-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-02-01

Study Completion Date

2032-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma Leukemia Lymphoid Leukemia Multiple Myeloma Myeloid Leukemia Monocytic Leukemia Non-hodgkin Lymphoma Other Hematologic Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm-Supervised

intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Group Type EXPERIMENTAL

Supervised Exercise and Coaching

Intervention Type BEHAVIORAL

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Enhanced Usual Care-Virtual Gym

enhanced usual care arm, where survivors will get access to virtual gym membership only.

Group Type ACTIVE_COMPARATOR

Virtual Gym Membership

Intervention Type BEHAVIORAL

This arm will get access to a virtual gym membership only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Supervised Exercise and Coaching

Intervention arm incorporating virtually supervised moderate-intensity aerobic exercise and behavioral intervention/coaching to improve adherence

Intervention Type BEHAVIORAL

Virtual Gym Membership

This arm will get access to a virtual gym membership only

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥50 years
2. A history of hematological malignancy
3. Participants must be able to and willingly give informed consent

Exclusion Criteria

1. Patients receiving intensive induction or consolidation chemotherapy. Maintenance chemotherapy, or lower-intensity chemotherapy for an indolent hematological malignancy is allowed.
2. Neurodegenerative disease (e.g. Alzheimer's dementia), stroke, or uncontrolled psychotic disorders (e.g. schizophrenia or bipolar disorder) in the past 3 months if those disorders are considered significant enough to impair participation in the study.
3. Illnesses such as clinical evidence of decompensated heart failure, unstable angina, or orthopedic or neuromuscular disorders that could limit safe participation in aerobic exercise.
4. Cardiopulmonary exercise test results that preclude safe exercise (e.g., life-threatening arrhythmia, balance difficulties, peak VO2 \<10 ml/kg/min).
5. Estimated life expectancy of less than 6 months (that precludes assessment of study primary endpoint).
6. Participants who do not plan to follow up at the participating center.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Nebraska

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Taylor Johnson

Role: CONTACT

Phone: 402-559-4596

Email: [email protected]

IIT OFFICE

Role: CONTACT

Phone: 402-559-4596

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

IIT Office IIT Office

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

606-25-FB

Identifier Type: -

Identifier Source: org_study_id